SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients (Q39622403)

13 September 2017

SLCO1B1 genetic polymorphism influences mycophenolic acid tolerance in renal transplant recipients (English)

1 reference

13 September 2017

4

Lina Quteineh

0 references

author name string

Hugues Michelon

1

1 reference

13 September 2017

Jörg König

2

1 reference

13 September 2017

Antoine Durrbach

3

1 reference

13 September 2017

Lina Quteineh

4

1 reference

13 September 2017

Céline Verstuyft

5

1 reference

13 September 2017

Valérie Furlan

6

1 reference

13 September 2017

Sophie Ferlicot

7

1 reference

13 September 2017

Alexia Letierce

8

1 reference

13 September 2017

Bernard Charpentier

9

1 reference

13 September 2017

Martin F Fromm

10

1 reference

13 September 2017

Laurent Becquemont

11

1 reference

13 September 2017

1 December 2010

1 reference

13 September 2017

1 reference

13 September 2017

11

1 reference

13 September 2017

12

1 reference

13 September 2017

1703-1713

1 reference

Mycophenolate mofetil in renal allograft recipients: a pooled efficacy analysis of three randomized, double-blind, clinical studies in prevention of rejection. The International Mycophenolate Mofetil Renal Transplant Study Groups

13 September 2017

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Mycophenolate mofetil and its mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Clinical pharmacokinetics of mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Characterization of a phase 1 metabolite of mycophenolic acid produced by CYP3A4/5.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Identification of glucoside and carboxyl-linked glucuronide conjugates of mycophenolic acid in plasma of transplant recipients treated with mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Opportunities for therapeutic monitoring of mycophenolate mofetil dose in renal transplantation suggested by the pharmacokinetic/pharmacodynamic relationship for mycophenolic acid and suppression of rejection

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

A double absorption-phase model adequately describes mycophenolic acid plasma profiles in de novo renal transplant recipients given oral mycophenolate mofetil

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Therapeutic drug monitoring of mycophenolate mofetil in transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Therapeutic monitoring of mycophenolate in transplantation: is it justified?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Influence of nonsynonymous polymorphisms of UGT1A8 and UGT2B7 metabolizing enzymes on the formation of phenolic and acyl glucuronides of mycophenolic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Influence of SLCO1B1, 1B3, 2B1 and ABCC2 genetic polymorphisms on mycophenolic acid pharmacokinetics in Japanese renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

UGT genotype may contribute to adverse events following medication with mycophenolate mofetil in pediatric kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

The impact of P-glycoprotein and Mrp2 on mycophenolic acid levels in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

The role of organic anion-transporting polypeptides and their common genetic variants in mycophenolic acid pharmacokinetics.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

The influence of macrolide antibiotics on the uptake of organic anions and drugs mediated by OATP1B1 and OATP1B3.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

A new JAVA interface implementation of THESIAS: testing haplotype effects in association studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Transporters and drug therapy: implications for drug disposition and disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Role of OATP transporters in the disposition of drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1)

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

SLCO1B1 variants and statin-induced myopathy--a genomewide study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Plasma concentrations of mycophenolic acid acyl glucuronide are not associated with diarrhea in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Risk of diarrhoea in a long-term cohort of renal transplant patients given mycophenolate mofetil: the significant role of the UGT1A8 2 variant allele

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Cyclosporine interacts with mycophenolic acid by inhibiting the multidrug resistance-associated protein 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Mechanism-based enterohepatic circulation model of mycophenolic acid and its glucuronide metabolite: assessment of impact of cyclosporine dose in Asian renal transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

UGT1A9 -275T>A/-2152C>T polymorphisms correlate with low MPA exposure and acute rejection in MMF/tacrolimus-treated kidney transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Influence of UDP-glucuronosyltransferase polymorphisms on mycophenolate mofetil-induced side effects in kidney transplant patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T > C polymorphism

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2FPGS.10.132

21 January 2018

Identifiers

DOI

10.2217/PGS.10.132

1 reference

13 September 2017

1 reference